Our Story

Dr. Andy Peters is Managing Director of Arpexas (Scotland) Ltd, a consultancy company providing support to the animal health sector in new product development, lead seeking and knowledge transfer, with special emphasis on vaccines and production medicine.  His particular expertise is in vaccine development and regulation.

Arpexas Ltd. was incorporated in 2006 as an animal health consultancy and has operated since then to advise and support international clients in the development of veterinary vaccines, pharmaceuticals and diagnostics.  The clientele has included some 50-60 entities ranging from global animal health companies, SME companies, universities, research institutes, government departments and charities.

In 2014 the company relocated to Scotland and was re-incorporated as Arpexas (Scotland) Ltd. 

Both Arpexas and Arpexas (Scotland) Ltd. operate via and extensive international network of specialist associates. Andy is a longstanding member of the Association of Veterinary Consultants.

The veterinary charity the Global Alliance for Livestock Veterinary Medicines (GALVmed) became an early client and through that the company became actively involved in development of veterinary medicines for lower and middle income countries (LMICs).  ARP acted as Chief Scientific Adviser over several years and acted as interim CEO between 2012 and 2013.

Also over a 3 year-period (2009-2012), he was Vice President, Animal Health for the SME AspenBio Pharma Inc. based in Denver, Colorado, developing recombinant gonadotrophin hormones. This technology is now licensed to Ceva for full development and commercialisation.

Until November 2005 Andy was Head of European Vaccine R&D with Pfizer Animal Health (now Zoetis).  Between 1993 and 1998 he was Professor of Animal  Health and Production at the Royal Veterinary College, London and previously Regulatory Manager with Hoechst Animal Health.

He is a former member of the UK  DEFRA Veterinary Products Committee (VPC) over 17 years and special adviser on approval of the bovine TB BCG vaccine.  He is also a member of the DEFRA Advisory Committee on Releases into the Environment (ACRE).  He is a Board trustee of a charity SMArt (Safe Medicines for Animals – regulatory training) and of the Soulsby Foundation. He is a member of the Governing Council of the Livestock Vaccine Innovation Fund of the Canadian government.

He is a veterinarian with PhD and DSc degrees in animal science.  He has published some 180 scientific papers and two books on Vaccines for Veterinary Applications and Reproduction in Cattle respectively.

He is also currently Professor of Tropical Veterinary Medicine at the University of Edinburgh and Director of SEBI-livestock, the Centre for Supporting Evidence Based Interventions, which focuses on improving the flow of quality data on farm livestock health and productivity in lower and middle income countries (LMICs).

"We work extensively in both the developed economies and lower and middle income countries, especially Africa, but the problems are the same, the farmer whether wealthy or poor still needs the affordable medicines to ensure good health in his/her animals. " - Dr. Peters


Current Projects

  • 3 year contract with Bill and Melinda Gates Foundation (BMGF) to facilitate and advance three products for application in LMICs:
    • Develop a ‘fill-finish’ capability for foot and mouth disease vaccine at the National Veterinary Research Institute, Nigeria and to promote the use of FMD vaccination amongst livestock farmers in Nigeria.
    • Develop a robust cow-side progesterone test to help fertility management of dairy cattle in Nigeria and India.
    • Develop a candidate vaccine for Campylobacter in village poultry in LMICs.

  • Working with BMGF to develop strategies for:
    • Transformation of the livestock sector in Kenya..
    • Optimal design of a national FMD vaccination programme for India.

  • Provide specialist advice on veterinary vaccines and their development for low and middle income countries (LMICs) to the International Development Research Centre, Canada; and member of the Governance Steering Committee of their Livestock Vaccine Innovation Fund initiative.

  • Evaluation of the objectives and performance of the International Veterinary Vaccine Network.
Contact Us

Previous Projects

  • Developed proposal for a global Animal Health company for a multi-million dollar grant for market development in Africa.
  • Provided expert report for international Animal Health company on the categorisation of veterinary vaccine pipeline.
  • Author of several reports on veterinary vaccines, diagnostics, aquaculture products, biopharmaceuticals for the HIS Markit organisation and its predecessor Animal Pharm.
  • Consultant to the UK Veterinary Medicines Directorate on the evaluation of the bovine BCG vaccine for TB in cattle and assistance to DEFRA (the licence applicant) on the further requirements needed to achieve the requirements to permit a clinical field trial.
  • Advice to a major global animal health company on a strategic plan to develop a multivalent vaccine for bovine respiratory disease in calves.
  • Assessment of market potential of novel animal health products and technologies for use in farm livestock.
  • Advice to a start-up SME on development of a needle-free vaccination technology for use in pigs.
  • Advice to investor organisations on the potential value and technical feasibility of novel technology platforms for applications in animal health.

A Culture Based on Collaboration

As a company at the forefront of developing animal health solutions including vaccines, and cutting-edge technologies, we are deeply rooted in a culture of collaboration. Our work, especially in Public-Private Partnerships (PPPs) in Low- and Middle-Income Countries (LMICs), exemplifies our commitment to partnership-driven innovation. We believe that the key to impactful advancements in veterinary medicine lies in uniting diverse expertise from various sectors. By working closely with governments, local communities, international agencies, and academia, we aim to tailor our solutions to meet the specific needs of these regions. Our collaborative approach not only accelerates technological advancements but also ensures that the benefits of our innovations reach those who need them most, fostering sustainable improvements in global animal health